Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. (October 2022) - Macy, M.; Cash, T.; Pinto, N.; Pressey, J.G.; Szalontay, L.; Furman, W.L.; Bukowinski, A.; Foster, J.H.; Friedman, G.K.; HaDuong, J.; Fox, E.; Weigel, B.J.; et al.